26-Jan-2026
Cathie Wood's weekly recap: buys WeRide, crypto names, trims defense firm Kratos, PINS, META
Seeking Alpha News (Tue, 27-Jan 6:15 AM ET)
Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide
TipRanks (Mon, 26-Jan 10:30 PM ET)
Cathie Wood Loads Up on Broadcom and Crypto Stocks, Trims Meta by $8M Ahead of Q4. Here’s Why
TipRanks (Mon, 26-Jan 7:39 AM ET)
Cathie Wood Buys the Dip in Broadcom and Crypto Stocks, Dumps Meta Shares
TipRanks (Sun, 25-Jan 7:25 PM ET)
Cathie Wood Buys the Dip in Broadcom and Crypto Stocks, Sells $8M in Meta
TipRanks (Sat, 24-Jan 8:30 AM ET)
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
PRNewswire (Thu, 22-Jan 4:05 PM ET)
Market Chameleon (Mon, 12-Jan 4:17 AM ET)
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
PRNewswire (Mon, 12-Jan 9:11 AM ET)
PRNewswire (Mon, 12-Jan 9:10 AM ET)
PRNewswire (Mon, 12-Jan 9:00 AM ET)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10X Genomics trades on the NASDAQ stock market under the symbol TXG.
As of January 26, 2026, TXG stock price climbed to $22.50 with 1,455,495 million shares trading.
TXG has a beta of 1.81, meaning it tends to be more sensitive to market movements. TXG has a correlation of 0.22 to the broad based SPY ETF.
TXG has a market cap of $2.85 billion. This is considered a Mid Cap stock.
Last quarter 10X Genomics reported $149 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.07.
In the last 3 years, TXG traded as high as $63.57 and as low as $6.78.
The top ETF exchange traded funds that TXG belongs to (by Net Assets): ARKK, ARKG, IWM, VTI, VB.
TXG has outperformed the market in the last year with a price return of +51.9% while the SPY ETF gained +15.1%. TXG has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +63.4% and +13.6%, respectively, while the SPY returned +2.6% and -0.3%, respectively.
TXG support price is $21.35 and resistance is $23.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXG shares will trade within this expected range on the day.
